Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.
extracellular vesicles
immunosuppression
melanoma
premetastatic niche
sentinel lymph node
stromal cells
tumor-secretory factors
Journal
Trends in immunology
ISSN: 1471-4981
Titre abrégé: Trends Immunol
Pays: England
ID NLM: 100966032
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
15
06
2023
revised:
10
07
2023
accepted:
11
07
2023
pmc-release:
01
09
2024
medline:
28
8
2023
pubmed:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
The natural history of advanced malignant melanoma demonstrates that, in most cases, widespread tumor dissemination is preceded by regional metastases involving tumor-draining lymph nodes [sentinel lymph nodes (SLNs)]. Under physiological conditions, LNs play a central role in immunosurveillance to non-self-antigens to which they are exposed via afferent lymph. The dysfunctional immunity in SLNs is mediated by tumor secretory factors that allow the survival of metastatic melanoma cells within the LN by creating a premetastatic niche (PMN). Recent studies outline the altered microenvironment of LNs shaped by melanoma mediators. Here, we discuss tumor secretory factors involved in subverting tumor immunity and remodeling LNs and highlight emerging therapeutic strategies to reinvigorate antitumoral immunity in SLNs.
Identifiants
pubmed: 37573226
pii: S1471-4906(23)00136-9
doi: 10.1016/j.it.2023.07.002
pmc: PMC10528107
mid: NIHMS1917497
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
724-743Subventions
Organisme : NCI NIH HHS
ID : R01 CA260259
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests There are no interests to declare.
Références
Elife. 2019 Dec 24;8:
pubmed: 31872800
Microcirculation. 2011 Apr;18(3):172-82
pubmed: 21166932
Cells. 2021 Sep 29;10(10):
pubmed: 34685565
Nat Immunol. 2016 Sep;17(9):1118-27
pubmed: 27400148
Adv Sci (Weinh). 2023 Feb;10(5):e2206001
pubmed: 36526596
Cancer Discov. 2022 May 2;12(5):1314-1335
pubmed: 35262173
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33430113
Cancer Immunol Res. 2017 Nov;5(11):969-977
pubmed: 28935649
Cancers (Basel). 2022 Nov 29;14(23):
pubmed: 36497391
Front Immunol. 2017 Mar 29;8:358
pubmed: 28424693
J Oncol. 2021 Jan 28;2021:6610769
pubmed: 33574842
Nature. 2011 Nov 13;479(7374):542-6
pubmed: 22080953
Br J Cancer. 2015 May 26;112(11):1772-81
pubmed: 25942396
Genes Cancer. 2011 Dec;2(12):1146-58
pubmed: 22866206
Clin Cancer Res. 2020 Oct 15;26(20):5520-5533
pubmed: 32591463
Cell Rep. 2019 Nov 26;29(9):2810-2822.e5
pubmed: 31775047
Cancer Res. 2019 Jan 1;79(1):183-195
pubmed: 30425059
Int J Cancer. 2019 Oct 1;145(7):1946-1957
pubmed: 30873585
Melanoma Res. 2021 Aug 1;31(4):328-337
pubmed: 34054059
Mod Pathol. 2001 Jun;14(6):604-8
pubmed: 11406663
Int J Cancer. 2019 Apr 1;144(7):1645-1656
pubmed: 30230526
Oncogenesis. 2020 Feb 14;9(2):22
pubmed: 32060259
Sci Immunol. 2021 Oct;6(64):eabg7836
pubmed: 34597124
Int J Mol Sci. 2020 Oct 21;21(20):
pubmed: 33096748
Mol Cancer. 2020 Jun 5;19(1):102
pubmed: 32503543
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638342
Cancer Immunol Res. 2015 Dec;3(12):1356-63
pubmed: 26297710
Clin Cancer Res. 2009 Mar 15;15(6):1931-9
pubmed: 19240164
Cancer Res. 2019 Sep 15;79(18):4715-4728
pubmed: 31337655
Nature. 2017 Jun 28;546(7660):676-680
pubmed: 28658220
Nat Commun. 2013;4:1853
pubmed: 23673638
Ann Surg Oncol. 2005 Aug;12(8):587-96
pubmed: 16021533
Clin Cancer Res. 2021 Sep 1;27(17):4859-4869
pubmed: 34187852
J Invest Dermatol. 2018 Jul;138(7):1627-1635
pubmed: 29474942
J Biomed Sci. 2022 Oct 20;29(1):84
pubmed: 36266717
BMC Cancer. 2021 May 29;21(1):641
pubmed: 34051744
Clin Cancer Res. 2005 Jan 1;11(1):107-12
pubmed: 15671534
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32788238
Front Immunol. 2022 Dec 05;13:1024039
pubmed: 36544759
J Clin Invest. 2018 Dec 3;128(12):5505-5516
pubmed: 30260323
Nat Commun. 2015 Apr 30;6:6993
pubmed: 25925867
Immunity. 2021 Sep 14;54(9):2117-2132.e7
pubmed: 34525340
Oncoimmunology. 2019 Sep 30;8(12):e1667742
pubmed: 31741769
Mol Carcinog. 2019 Sep;58(9):1670-1679
pubmed: 31099111
Cell Rep. 2018 Dec 26;25(13):3554-3563.e4
pubmed: 30590031
Immunity. 2006 Jul;25(1):153-62
pubmed: 16860764
Cancer Res. 2006 Aug 1;66(15):7766-74
pubmed: 16885380
J Proteomics. 2018 Mar 1;174:1-8
pubmed: 29275043
Clin Cancer Res. 2007 Jun 1;13(11):3125-32
pubmed: 17545514
Blood. 2011 Sep 1;118(9):2502-10
pubmed: 21750314
Clin Cancer Res. 2022 May 13;28(10):1996-1998
pubmed: 35262676
Br J Dermatol. 2022 Apr;186(4):694-704
pubmed: 34773645
Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):17-30
pubmed: 15946832
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34642246
Cancers (Basel). 2020 Feb 17;12(2):
pubmed: 32079286
Sci Adv. 2022 Jun 10;8(23):eabl5162
pubmed: 35675399
Front Cell Dev Biol. 2023 Jan 10;10:1061982
pubmed: 36704194
Cell Mol Life Sci. 2021 Aug;78(16):5987-6002
pubmed: 34241649
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Int J Mol Sci. 2020 Nov 01;21(21):
pubmed: 33139674
Nat Rev Cancer. 2012 Feb 24;12(3):210-9
pubmed: 22362216
Int J Mol Sci. 2022 Mar 22;23(7):
pubmed: 35408802
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):104-114
pubmed: 32561502
Oncogene. 2020 Jul;39(30):5267-5281
pubmed: 32561850
Elife. 2018 May 01;7:
pubmed: 29712618
Immunity. 2019 Sep 17;51(3):561-572.e5
pubmed: 31402260
Cancer Lett. 2022 Oct 1;545:215841
pubmed: 35921973
Asia Pac J Clin Oncol. 2018 Dec;14(6):383-391
pubmed: 29575602
Cancer Res. 2011 Oct 15;71(20):6547-57
pubmed: 21868759
Clin Cancer Res. 2022 May 13;28(10):2069-2081
pubmed: 35046061
Pigment Cell Melanoma Res. 2019 Nov;32(6):777-791
pubmed: 31172672
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32436938
Exp Cell Res. 2004 May 1;295(2):315-29
pubmed: 15093732
Sci Rep. 2021 Oct 29;11(1):21314
pubmed: 34716378
Clin Exp Metastasis. 2022 Feb;39(1):159-179
pubmed: 34767139
Adv Surg. 2007;41:241-56
pubmed: 17972569
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
Cancer Res. 2022 May 3;82(9):1774-1788
pubmed: 35502542
Cancer Immunol Immunother. 2021 Feb;70(2):475-483
pubmed: 32814992
Cancer Immunol Immunother. 2022 Aug;71(8):2029-2040
pubmed: 35018481
Cancer Res. 2020 Sep 1;80(17):3463-3465
pubmed: 32605997
Mod Pathol. 2005 Sep;18(9):1232-42
pubmed: 15803182
J Exp Med. 2019 May 6;216(5):1091-1107
pubmed: 30975896
Science. 2019 Feb 8;363(6427):644-649
pubmed: 30733421
Cancer Cell. 2023 Mar 13;41(3):546-572
pubmed: 36917952
N Engl J Med. 2022 Dec 8;387(23):2113-2125
pubmed: 36477031
Front Immunol. 2021 Aug 17;12:736670
pubmed: 34484246
Cancer Cell. 2023 Mar 13;41(3):374-403
pubmed: 36917948
J Natl Compr Canc Netw. 2016 Apr;14(4):450-73
pubmed: 27059193
Pigment Cell Res. 2000;13 Suppl 8:163-9
pubmed: 11041376
Crit Rev Immunol. 2021;41(2):45-76
pubmed: 34348002
JAMA Dermatol. 2022 May 1;158(5):495-503
pubmed: 35353115
Front Immunol. 2019 Feb 28;10:347
pubmed: 30891035
Sci Adv. 2021 Mar 24;7(13):
pubmed: 33762337
Cancer Immunol Res. 2015 May;3(5):495-505
pubmed: 25633713
Cell Commun Signal. 2022 Sep 19;20(1):146
pubmed: 36123693
Immunity. 2023 Jan 10;56(1):107-124.e5
pubmed: 36580918
Int J Mol Sci. 2020 Oct 13;21(20):
pubmed: 33066331
Cancer Immunol Res. 2022 Dec 2;10(12):1525-1541
pubmed: 36206577
Immunol Lett. 2012 Nov-Dec;148(1):34-8
pubmed: 22898052
Melanoma Res. 2021 Aug 1;31(4):338-351
pubmed: 33965973
Cancer Immunol Immunother. 2020 Nov;69(11):2319-2331
pubmed: 32507967
Cancer Res. 2020 May 15;80(10):1942-1956
pubmed: 32127354
PLoS One. 2016 Mar 24;11(3):e0151848
pubmed: 27010197
Trends Immunol. 2021 Sep;42(9):782-794
pubmed: 34362676
Mod Pathol. 2011 Apr;24(4):487-94
pubmed: 21151098
Front Immunol. 2015 Mar 13;6:114
pubmed: 25821451
Cytokine. 2018 May;105:63-72
pubmed: 29459345
J Extracell Vesicles. 2022 Feb;11(2):e12197
pubmed: 35188342
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
J Pathol. 2018 Dec;246(4):447-458
pubmed: 30101525
PLoS Biol. 2020 Apr 6;18(4):e3000704
pubmed: 32251437
Nat Commun. 2014 Dec 04;5:5639
pubmed: 25472612
Cancers (Basel). 2023 Mar 16;15(6):
pubmed: 36980693
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2521-6
pubmed: 25659743
J Exp Med. 2005 Apr 4;201(7):1089-99
pubmed: 15809353
Cancer Immunol Res. 2020 Aug;8(8):990-1003
pubmed: 32580941
Sci Adv. 2020 Feb 26;6(9):eaax3223
pubmed: 32133394
J Cell Biochem. 2016 Jul;117(7):1697-706
pubmed: 26666522
J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):77-84
pubmed: 7804530
Curr Oncol Rep. 2021 May 18;23(7):83
pubmed: 34003395
Oncoimmunology. 2015 Jun 1;4(8):e1026504
pubmed: 26405583
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Cancers (Basel). 2010 May 07;2(2):794-808
pubmed: 24281094
Int J Clin Exp Pathol. 2018 Sep 01;11(9):4630-4636
pubmed: 31949862
Immunology. 2022 Jun;166(2):249-264
pubmed: 35318648
Int J Mol Sci. 2022 Sep 07;23(18):
pubmed: 36142212
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Sci Adv. 2023 Apr 14;9(15):eadd1992
pubmed: 37043573
Science. 2016 Apr 8;352(6282):242-6
pubmed: 26989197
Melanoma Res. 2016 Oct;26(5):429-41
pubmed: 27455380
Cell Rep. 2022 Mar 1;38(9):110447
pubmed: 35235800
J Am Coll Surg. 2021 Apr;232(4):517-524.e1
pubmed: 33316426
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824741
Elife. 2021 Nov 09;10:
pubmed: 34751648
Nat Cancer. 2021 Dec;2(12):1387-1405
pubmed: 34957415
Nat Commun. 2020 Aug 17;11(1):4113
pubmed: 32807791
J Cell Mol Med. 2022 Dec;26(23):5743-5754
pubmed: 36398426
Cell Cycle. 2019 Nov;18(22):3085-3094
pubmed: 31544590
J Immunol. 2008 Nov 1;181(9):6189-200
pubmed: 18941209
Eur J Cancer. 2020 Sep;137:175-182
pubmed: 32781392